These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1452 related articles for article (PubMed ID: 32767662)

  • 1. Exosomal lncRNA H19 promotes the progression of hepatocellular carcinoma treated with Propofol via miR-520a-3p/LIMK1 axis.
    Wang D; Xing N; Yang T; Liu J; Zhao H; He J; Ai Y; Yang J
    Cancer Med; 2020 Oct; 9(19):7218-7230. PubMed ID: 32767662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DANCR promotes HCC progression and regulates EMT by sponging miR-27a-3p via ROCK1/LIMK1/COFILIN1 pathway.
    Guo D; Li Y; Chen Y; Zhang D; Wang X; Lu G; Ren M; Lu X; He S
    Cell Prolif; 2019 Jul; 52(4):e12628. PubMed ID: 31038266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA SNHG16 promotes non-small cell lung cancer development through regulating EphA2 expression by sponging miR-520a-3p.
    Yu L; Chen D; Song J
    Thorac Cancer; 2020 Mar; 11(3):603-611. PubMed ID: 31953899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
    Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
    Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LINC01116 targets miR-520a-3p and affects IL6R to promote the proliferation and migration of osteosarcoma cells through the Jak-stat signaling pathway.
    Zhang B; Yu L; Han N; Hu Z; Wang S; Ding L; Jiang J
    Biomed Pharmacother; 2018 Nov; 107():270-282. PubMed ID: 30098545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Exosomal CircNEK9 Accelerates the Progression of Gastric Cancer via miR-409-3p/MAP7 Axis.
    Yu L; Xie J; Liu X; Yu Y; Wang S
    Dig Dis Sci; 2021 Dec; 66(12):4274-4289. PubMed ID: 33449227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA HCG11 accelerates the progression of hepatocellular carcinoma via miR-26a-5p/ATG12 axis.
    Li ML; Zhang Y; Ma LT
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10708-10720. PubMed ID: 31858580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA HOTAIR promotes hepatocellular carcinoma progression by regulating miR-526b-3p/DHX33 axis.
    Liu Z; Ouyang G; Lu W; Zhang H
    Genes Genomics; 2021 Aug; 43(8):857-868. PubMed ID: 33843021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC.
    Li Z; Wu G; Li J; Wang Y; Ju X; Jiang W
    BMC Cancer; 2020 Apr; 20(1):282. PubMed ID: 32252678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HOXA-AS2 Promotes Proliferation and Induces Epithelial-Mesenchymal Transition via the miR-520c-3p/GPC3 Axis in Hepatocellular Carcinoma.
    Zhang Y; Xu J; Zhang S; An J; Zhang J; Huang J; Jin Y
    Cell Physiol Biochem; 2018; 50(6):2124-2138. PubMed ID: 30415263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA SNHG1 promotes cell progression and metastasis via sponging miR-377-3p in hepatocellular carcinoma.
    Qu A; Yang Q
    Neoplasma; 2020 May; 67(3):557-566. PubMed ID: 32122143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA HCG18 contributes to the progression of hepatocellular carcinoma via miR-214-3p/CENPM axis.
    Zou Y; Sun Z; Sun S
    J Biochem; 2020 Nov; 168(5):535-546. PubMed ID: 32663252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling.
    Xie CF; Feng KL; Wang JN; Luo R; Fang CK; Zhang Y; Shen CP; Zhong C
    J Ethnopharmacol; 2022 Aug; 294():115360. PubMed ID: 35568116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214.
    Huang X; Gao Y; Qin J; Lu S
    Am J Physiol Gastrointest Liver Physiol; 2018 May; 314(5):G559-G565. PubMed ID: 29097358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway.
    Guo X; Wang Y
    Cancer Med; 2020 Jul; 9(14):5235-5246. PubMed ID: 32462698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long noncoding RNA matrilineal expression gene 3 inhibits hepatocellular carcinoma progression by targeting microRNA-5195-3p and regulating the expression of forkhead box O1.
    Li M; Liao H; Wu J; Chen B; Pang R; Huang J; Zhu Y
    Bioengineered; 2021 Dec; 12(2):12880-12890. PubMed ID: 34895065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exosomal circPACRGL promotes progression of colorectal cancer via the miR-142-3p/miR-506-3p- TGF-β1 axis.
    Shang A; Gu C; Wang W; Wang X; Sun J; Zeng B; Chen C; Chang W; Ping Y; Ji P; Wu J; Quan W; Yao Y; Zhou Y; Sun Z; Li D
    Mol Cancer; 2020 Jul; 19(1):117. PubMed ID: 32713345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
    Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
    Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long Noncoding RNA MALAT1 Regulates Hepatocellular Carcinoma Growth Under Hypoxia via Sponging MicroRNA-200a.
    Zhao ZB; Chen F; Bai XF
    Yonsei Med J; 2019 Aug; 60(8):727-734. PubMed ID: 31347327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 73.